Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) Nexus 2017

Looking Ahead at the Specialty Drug Pipeline After an Active Year of Approvals

Christina Mattina
Aimee Tharaldson, PharmD, of Express Scripts kicked off the Academy of Managed Care Pharmacy (AMCP) 2017 Nexus, held October 16-19 in Dallas, Texas, with a presentation on the pipeline of specialty pharmaceuticals in development.
Year after year, AMCP Nexus attendees rely on Tharaldson to provide insights into the specialty drug pipeline, and she did not disappoint. Experts crowded into a ballroom to hear her discuss the current specialty treatment options and future trends in 9 main classes of conditions.
For example, 7 drugs for inflammatory conditions are expected to receive a decision from the FDA within 2018, with news on golimumab for psoriatic arthritis and ankylosing spondylitis due next week.
In the cancer space, a second CAR T-cell therapy, Juno Therapeutics’ JCAR017 for treating B-cell non-Hodgkin lymphoma, should receive an FDA decision sometime in 2018. However, about 40% of the cancer drugs in the current pipeline are oral medications. Similarly, 9 of 10 of the drugs in the pipeline for nonalcoholic steatohepatitis are oral drugs.
Tharaldson also discussed the 3 new drugs in the hemophilia pipeline. One of them, emicizumab, is a monoclonal antibody that replaces the activity of Factor VII, and its manufacturer Genentech is confident it will be approved later this year.
According to Tharaldson, the upcoming pipeline for migraine therapies is dominated by calcitonin gene-related peptide receptor inhibitors, some of which may be delivered in monthly injections.
In contrast, some therapy classes are moving more slowly. The pipeline for hepatitis C therapies is fairly quiet due to market saturation, and any drugs for treating progressive multiple sclerosis are not expected until at least 2020. Alzheimer’s disease is another difficult class; its prospective pipeline includes immunotherapies like anti-amyloid β antibodies and oral drugs like BACE inhibitors, but none are up for approval until 2020 and beyond.
Tharaldson also highlighted some miscellaneous specialty drugs that are pending approval, like Intarcia's ITCA 650 with exenatide, which is an implantable minipump for treating type 2 diabetes that is expected to receive approval this November. Benralizumab, an injectable asthma therapy, is due for an approval by December, and its indications could expand to include chronic obstructive pulmonary disease in 2018.
Not all specialty drugs have such a rosy outlook, Tharaldson noted. Ataluren, a protein restoration therapy for the rare disease Duchenne muscular dystrophy, is due for a decision by October 24 after being submitted “under protest”; Tharaldson estimated it had just a 10% chance of approval next week.

Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up